Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...
Hims & Hers (HIMS) fell 22% after Amazon (AMZN) announced it was entering the hair loss and erectile dysfunction treatment ...
Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...
Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...
Citi analyst Daniel Grosslight has maintained their neutral stance on HIMS stock, giving a Hold rating on November 6. Daniel ...
The tech giant said it would offer upfront, monthly pricing for customers seeking consultations and medications for five ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Last week, Hims & Hers Health (NYSE:HIMS) dropped another mic with its latest earnings, and the numbers are mind-blowing.
BofA analyst Allen Lutz downgraded Hims & Hers to Underperform from Buy. Published first on TheFly – the ultimate source for ...